Skye Bioscience
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11250 El Camino Real Ste 100, San Diego,...Phone Number
(858) 410-0266Website
www.skyebioscience.comRevenue
$55.6 MillionStock Symbol
SKYEIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Skye Bioscience
Skye Bioscience is a pharmaceutical company developing proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions.Explore more
Skye Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Skye Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Skye Bioscience has recently received funding, and reach out quickly before it becomes old news!
Check out if Skye Bioscience is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Skye Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Skye Bioscience has new funding data
Click to see if Skye Bioscience had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Skye Bioscience
Earning: See what the market has to say on Skye Bioscience recently announced quarterly report
Product Launch: Get notified when Skye Bioscience launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Skye Bioscience as Masked Content
Find more new buyers
Compare Similar Companies to Skye Bioscience
Compare insights from companies similar to Skye Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Skye Bioscience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Skye Bioscience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Skye Bioscience.
Skye Bioscience financials insights
Gather financial insights about Skye Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$16.6M
2020
Share Placement
$7M
2024
Share Placement
$50.3M
Skye Bioscience Tech Stack
A closer look at the technologies used by Skye Bioscience
Most Recent Scoops
Project
Skye Bioscience has positioned nimacimab as the core value driver, with the APC data representing an interesting scaffold that supports a much broader combination platform over time. The unimolecular asset offers advantages from an IP perspective and leverages nimacimab's favorable half-life and safety profile, achieving GLP-1 receptor agonist engagement in the periphery with comparable weight loss to a true combination using three-day dosing versus daily dosing with semaglutide or SBI-403.
Product Development, Pharmaceuticals
Product Launch
Skye Bioscience has reported that nimacimab 200 mg demonstrated a favorable safety profile with placebo-tolerability through 52 weeks, with no nimacimab-associated neuropsychiatric signal and no additive GI burden when combined with semaglutide.
Pharmaceuticals, Clinical Operations
Project
Skye Bioscience is using IV administration to provide the cleanest and fastest way to generate high exposure PK and safety information for nimacimab, while building a practical subcutaneous path with ENHANZE for Phase 2b. Based on a previous bioavailability study, the subcutaneous dose has a relative bioavailability compared to IV of about 56%, which Skye Bioscience uses as the conversion factor. The IV dose is expected to be about an hour in infusion time, with patients asked to stay on site longer for the first few doses to continue evaluating safety.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Skye Bioscience has reported that participants on semaglutide alone saw 38.7% of weight regained over 13 weeks, in line with the Step 1 extension study, while participants on the combination of nimacimab plus semaglutide only regained 17.8% over the same period.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Skye Bioscience News & Media
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. “Since our March update, execution has focused on turning CBeyond into a Phase 2Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16.Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Skye Bioscience
Sign Up For FreeTo access detailed company insights
Skye Bioscience is a pharmaceutical company developing proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions.... Read More
